May 01, 2025 a 12:31 pm
REGN: Analysts Ratings - Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. displays a strong portfolio of innovative pharmaceutical products addressing various serious conditions. With a robust development pipeline and strategic collaborations, the company remains a critical player in the biopharmaceutical industry. Despite pharmaceutical market challenges, Regeneron's diversified product line and strategic partnerships position the company for sustained growth.
Historical Stock Grades
The table below illustrates the most recent analyst ratings for Regeneron Pharmaceuticals, Inc., along with a visual representation of the sentiment score.
| Category | Number | Sentiment Score |
|---|---|---|
| Strong Buy | 7 | |
| Buy | 13 | |
| Hold | 5 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
Over recent months, the sentiment surrounding Regeneron has shown a notable stability with slight variances in ratings. Analyst strength in Buy and Strong Buy categories underscores sustained confidence, whereas Hold ratings suggest cautious optimism. The absence of Sell ratings reaffirms perceived resilience in the company's prospects.
- Subtle decrease in Buy ratings, reflecting slight reservation.
- Hold ratings reach a lower position, suggesting improved sentiment.
- Minor decline in Strong Sell ratings, indicating reduced pessimism.
Percentage Trends
The data reveals movements in analyst ratings that suggest slight cautiousness amidst ongoing evaluations. Adjustments depict adaptive strategies by analysts in assessing the company's outlook.
- Percentage of Buy ratings decreased from 41% to 39% over six months.
- Strong Buy ratings demonstrate consistent trust at 23%.
- Hold ratings experienced a slight decline from previous periods.
Latest Analyst Recommendations
The latest recommendations depict a consistent outlook for Regeneron, with most analysts maintaining their positions.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-30 | Outperform | Outperform | RBC Capital |
| 2025-04-30 | Neutral | Neutral | UBS |
| 2025-04-30 | Neutral | Neutral | Baird |
| 2025-04-30 | Outperform | Outperform | BMO Capital |
| 2025-04-30 | Overweight | Overweight | Wells Fargo |
Analyst Recommendations with Change of Opinion
Shifts in ratings reflect analysts' reassessments based on market dynamics and company performance. Upgrades indicate enhanced stock attractiveness, while downgrades suggest tempered expectations.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-02-05 | Outperform | Market Perform | Leerink Partners |
| 2025-01-16 | Neutral | Buy | UBS |
| 2024-09-24 | Market Perform | Outperform | Leerink Partners |
| 2024-01-12 | Outperform | Sector Perform | RBC Capital |
| 2023-11-03 | Outperform | Market Perform | Raymond James |
Interpretation
Analyst assessments indicate cautious optimism with steady confidence levels in Regeneron Pharmaceuticals, Inc. The stability of most analyst ratings, combined with some upgrades, suggests growing confidence in the company’s strategic direction and product efficiency. Limited Sell ratings reflect a general positive outlook, while slight variations in opinion demonstrate adaptations to emerging market conditions.
Conclusion
Regeneron Pharmaceuticals, Inc. displays a stable and favorable position in the analyst community, with consistent ratings in the Buy and Strong Buy categories. While minor fluctuations exist, the overall sentiment is one of sustained potential, driven by the company’s innovation and strategic partnerships. Balancing promising pharmaceutical developments with market uncertainties will be essential in maintaining positive analyst sentiment in the future.